Wezlana I.V. · DIN 02544210 · 130 mg/26 mL · injection solution-26mL vial
Limited Use, Reason for Use code 671, 672 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 671, 672 required
Write on scriptone applicable Reason for Use code, 671 or 672 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 671, 672
Reason for Use code 671
For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:
A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);
AND
B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);
OR
Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);
OR
Conventional treatment with a corticosteroid is contraindicated;
AND
C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.
*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.
The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).
The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.
Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.
Maintenance/Renewal:
Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.
Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.
Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.
Exclusion criteria (initial and renewal coverage):
- Combination therapy with another biologic used to treat inflammatory disease will not be funded.
Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 672
For the treatment of moderate to severe (luminal) Crohn's disease in patients who meet the following criteria:
A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn's disease);
AND
B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);
OR
Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate);
OR
Conventional treatment with a corticosteroid is contraindicated;
AND
C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.
The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).
The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.
Maintenance/Renewal:
Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.
Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.
Exclusion criteria (initial and renewal coverage):
- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.
Patients with mild Crohn's disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.
Patients with fistulising Crohn's disease may be considered on a case-by-case basis through the Exceptional Access Program.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Wezlana I.V. · DIN 02544210
Manufacturer: Amgen Canada Inc.; listing date 2024-04-30
Health Canada: Marketed since 2024-03-01 · brand WEZLANA I.V. · ATC L04AC05 USTEKINUMAB · form Solution · route Intravenous · ingredients USTEKINUMAB 5 MG/ML · company Amgen canada inc · schedule Schedule d, Prescription
Wezlana I.V.: Formulary list price $1248.00 per unit (the source does not state the unit; exact figure $1248.0000). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02544210)
Source record
DIN 02544210: Wezlana I.V.
Raw flags: sec12=Y, sec3=Y
Item: 920000785; group id 991; item number 2327; lccId 00389; manufacturer id AMG
Source form: Inj Sol-26mL Vial Pk; strength: 130mg/26mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1248.0000; ministry $1248.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02544210
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103274
Shortage status: not checked (no credentials)